David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011 he became Professor of Medical Microbiology at the University of East Anglia but with 30% of this time supplied back to Public Health England as its Lead on Antibiotic Resistance. He has broad interests on the evolution and dissemination of antibiotic resistance and its relationship to antibiotic prescribing. Prof Livermore sits on the British Society for Antimicrobial Chemotherapy's working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and its Antibiotic Action advisory board and is a member of the UK Government's Antimicrobial Resistance & Healthcare Infections Advisory Committee. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy, Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.
Dr. Peter Schneider
Peter Schneider obtained his Ph.D. in 1971 at the Swiss Federal Institute of Technology, Zürich (ETHZ). From 1971 he has worked for Ciba-Geigy in chemistry research developing antibiotics, anti-tumorals and antivirals and has been involved in several marketed products. He was responsible for building-up the Molecular Diversity unit (Compound Archive, Natural Products, Microbiological Transformations, and Combinatorial Chemistry) and was a member of the Steering Committee for the Ciba and Chiron collaboration. After the merger of Ciba with Sandoz to Novartis, he led the Combinatorial Chemistry unit introducing the single bead approach and other new technologies. In 2002 he was appointed as Head of Chemistry at Arpida Ltd. working in the field of anti-infectives. Currently, he is consulting for several small Biotech companies and is a member of Ki Consulting AG. He holds 31 issued patents and has published 39 articles in leading journals.
Dr. Christian Hubschwerlen
Christian worked for more than 20 years for Roche where he, amongst other things, co-led the department for infectious diseases. After that, he became VP of medicinal chemistry at Morphochem AG. Subsequently, Christian filled the role of Director and Senior Group Leader at Actelion’s Anti-Infectives Unit where he set up the group and shaped the research programs. Chemist by training he earned his PhD from the University of Haute Alsace and postdoced at the Woodward Research Institute. With his long lasting experience in the field and his track record, Christian supports BioVersys in Medicinal Chemistry and similar matters.
Prof. Martin Fussenegger
Martin is professor of biotechnology and bioengineering at the Swiss Federal Institute of Technology, the ETH Zurich. Prior to that Martin studied molecular biology and genetics at the Biocenter in Basel, performed his PhD at the Max Planck Institute of Biology in medical microbiology and was postdoctoral fellow at the Max Planck Institute of Infection Biology. In 1996, Martin joined James E. Baileys group at the ETH Zurich as independent group leader and received his habilitation in 2000. Currently he is the Chairman of the ETH Department of Biosystems Science and Engineering in Basel. Martin has published over 170 refereed research papers, is coinventor of several patents and received, for his contributions to drug discovery and cell engineering the de Vigier and the Elmar Gaden Awards in 2003, became a member of the American Institute for Medical and Biological Engineering in 2007 and was the first non-US recipient of the Merck Award in Cell Engineering in 2008. Martin is also co-inventor of BioVersys' core technology.